When Three Cycles of Pre-Surgery Chemotherapy End and You're Told "We Can't Give More, Even If You Pay" — Where the Cycle Number Actually Comes From, and What to Check Before Looking Abroad

Chemotherapy or immunotherapy given before surgery is called neoadjuvant therapy. When the planned cycles are finished and you are waiting for the response assessment, it feels natural to ask for a few more rounds if your body has tolerated them well. Hearing "we can't continue" — or "not even if you pay out of pocket" — can sound like a flat prohibition. In practice, that answer can come from four very different layers, and knowing which one applies changes what you should ask next.

The first layer is regulatory approval: each drug is approved for specific cancer types, stages, and settings. The second is insurance reimbursement criteria, which are set separately from approval and often specify the exact number of cycles covered. The third is clinical evidence and protocol: the number of neoadjuvant cycles is not arbitrary. It reflects the schedule tested in the trials that established the regimen, and there is usually no evidence that adding more cycles improves outcomes. The fourth is the surgical timeline: the purpose of neoadjuvant treatment is not to extend treatment time but to shrink the tumor and move to surgery at a planned point.

"Not even if you pay" usually points to the first two layers. In many health systems, including Korea's, a cancer drug cannot simply be given outside its approved indication or reimbursement rules just because the patient offers to cover the cost. Off-protocol use requires the hospital to go through a formal review and approval process, and whether it is granted depends on the case. That means the barrier may be procedural rather than a matter of your doctor's willingness — so it is worth asking separately whether the answer is "formally impossible" or "an application is possible, but the evidence does not support it here."

It also helps to name why you want more treatment. Fear that the response was incomplete, fear of the operation itself, and fear of later recurrence lead to different answers. If the response assessment is favorable, proceeding to surgery as planned is the standard path. If the response is insufficient, the usual next considerations are a change of regimen, alternative local treatment strategies including organ-preserving approaches, or enrollment in a clinical trial — the legitimate route to treatment beyond the standard range. Simply adding cycles without evidence raises the risk of cumulative toxicity, progression of non-responding disease, and a delayed operation. Immune checkpoint inhibitors can also cause thyroid, liver, bowel, or lung side effects weeks after the last dose, so who manages those, and where, is part of the plan.

If you still explore treatment abroad, check these axes before asking whether it is "possible": ① drug and indication — whether the same agent can be used there for the same stage and purpose, or whether it would also be off-label; ② continuity of side-effect care — which clinic at home will manage complications after you return, agreed in advance; ③ connection to the surgical team — whether your surgeons can coordinate the overseas schedule with the operation date; ④ records — English-language summaries, pathology reports, medication records, and original imaging, with slide or block loans handled as a separate request; ⑤ cost and insurance — what your policy reimburses overseas, prepayment and refund terms, interpretation fees, all documented; ⑥ intermediaries — informal brokers offer little protection if a dispute arises, and arrangements built on referral fees or large advance payments are especially risky. Contacting a hospital's official international patient office directly is safer.

In the clinic, this order shortens the conversation: what the response assessment showed and how operability is judged; which of the four layers is the actual reason for stopping; whether an exception application is possible in your case; whether an eligible clinical trial exists; and what the post-surgical treatment plan will be. With those five answers written down, any option — including going abroad — can be weighed against something concrete.

This article is general information and does not replace individual medical care. Decisions depend on stage, drug, and overall condition, so please discuss any change to your treatment plan, including treatment abroad, with your own medical team.